Developing a new method for delivering genes to the nervous system without surgery
Bioengineering of highly effective AAV vectors for noninvasive gene delivery to the nervous system
This study is exploring a new way to help heal damaged nerve cells in the brain and spinal cord using a special delivery system, which could be really helpful for people with spinal cord injuries or conditions like Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11075341 on NIH RePORTER |
What this research studies
This research focuses on creating a noninvasive method to deliver genes to specific neural cells in the central nervous system (CNS) using engineered AAV9 vectors. The goal is to enhance the ability to regenerate damaged nerve cells, particularly after spinal cord injuries. By testing these vectors in animal models, the researchers aim to determine how effectively they can target various types of neural cells and promote recovery. This innovative approach could lead to significant advancements in treating conditions like Alzheimer's disease and spinal cord injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults with spinal cord injuries or age-related neurological conditions such as Alzheimer's disease.
Not a fit: Patients with conditions unrelated to nerve regeneration or those who are not within the age range of 21 years and older may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking method for treating neurological conditions by promoting nerve regeneration.
How similar studies have performed: Previous research has shown promise in using AAV vectors for gene delivery, but this specific approach is novel and aims to improve efficacy significantly.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Li, Shuxin — Temple Univ of the Commonwealth
- Study coordinator: Li, Shuxin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.